期刊文献+
共找到6篇文章
< 1 >
每页显示 20 50 100
Effectiveness of hepatitis B virus vaccination program in Egypt:Multicenter national project 被引量:4
1
作者 Iman I Salama Samia M Sami +15 位作者 Zeinab Nabil Ahmed Said Manal H El-Sayed Lobna A El Etreby Thanaa M Rabah Dalia M Elmosalami Amany T Abdel Hamid Somaia I Salama Aida M Abdel Mohsen Hanaa M Emam Safaa M Elserougy Amal I Hassanain Naglaa F Abd Alhalim Fatma A Shaaban Samia A Hemeda Nihad A Ibrahim Ammal M Metwally 《World Journal of Hepatology》 CAS 2015年第22期2418-2426,共9页
AIM:To assess the effectiveness of hepatitis B virus(HBV) vaccination program among fully vaccinated children.METHODS:A national community based crosssectional study was carried out in 6 governorates representing Egyp... AIM:To assess the effectiveness of hepatitis B virus(HBV) vaccination program among fully vaccinated children.METHODS:A national community based crosssectional study was carried out in 6 governorates representing Egypt. A total of 3600 children aged from 9 mo to 16 years who were fully vaccinated with HBV vaccine during infancy were recruited. Face to face interviews were carried out and sera were evaluated for hepatitis B surface antigen(HBsA g),anti-HBV core antibodies(total) and quantitative detection of hepatitis B surface antibody using enzyme linked immunoassays techniques. Samples positive to HBs Ag/anti-HBV core antibodies were subjected to quantitative HBV-DNA detection by real time polymerase chain reaction with 3.8 IU/L detection limit. RESULTS:Sero-protection was detected among 2059 children(57.2%) with geometric mean titers 75.4 ± 3.6 IU/L compared to 3.1 ± 2.1 IU/L among nonseroprotected children. Multivariate logistic analysis revealed that older age and female gender were the significant predicting variables for having non seroprotective level,with adjusted odds ratio 3.3,9.1and 14.2 among children aged 5 to < 10,10 to < 15 and ≥ 15 years respectively compared to those < 5 years and 1.1 among girls compared to boys with P < 0.01. HBs Ag was positive in 0.11% and breakthrough infection was 0.36% and 0.39% depending on positivity of anti-HBc and DNA detection respectively. The prevalence of HBV infection was significantly higher among children aged ≥ 7 years(0.59%) compared to 0.07% among younger children with odds ratio equal to 8.4(95%CI:1.1-64.2) and P < 0.01.The prevalence was higher among girls(0.48%) than boys(0.29%) with P > 0.05. C ON C LU S I ON :T he E gy pt ian c ompuls or y H B V vaccination program provides adequate protection. Occult HBV infection exists among apparently healthy vaccinated children. Adherence to infection control measures is mandatory. 展开更多
关键词 Hepatitis B virus IMMUNIZATION seroprotection Brea
下载PDF
Prevaccination Antibody Confers Additional Immune Responses to Repeated Yearly Influenza Vaccination in an Elderly Population 被引量:1
2
作者 Satoko Kitamura Naoki Komatsu +2 位作者 Masahide Matsushita Hiromi Seo Seisho Takeuchi 《World Journal of Vaccines》 CAS 2022年第2期11-19,共9页
Annual vaccination is necessary to maintain humoral immunity in the elderly population. However, the factors influencing the response to influenza vaccination have not been completely identified. The aim of this study... Annual vaccination is necessary to maintain humoral immunity in the elderly population. However, the factors influencing the response to influenza vaccination have not been completely identified. The aim of this study was to explore the factors that influenced antibody responses to repeated vaccination using measures that were both objective and quantitative. A total of 111 volunteers aged > 61 years were vaccinated subcutaneously with one dose of influenza vaccine from the 2005-2006 season through the 2009-2010 season. The factors that influenced antibody responses after vaccination were evaluated. The seroprotection rates (PRs) were significantly higher in responders (subjects with a higher antibody titer in the 2005-2006 season) than in nonresponders only in the 2006-2007 and 2007-2008 seasons. PRs after vaccination were significantly higher in seropositive individuals (subjects with a higher prevaccination antibody titer in the 2006-2007 season) than in seronegative individuals for all three virus strains in almost all of the 5 years. Age, gender, and vaccination in the 2004-2005 season did not influence the response. These results suggest that an immune response at a certain time point would predict immune responses only in the near future. However, prevaccination antibody titer in the following season is the ideal predictor for future responses that last over several influenza seasons. 展开更多
关键词 Influenza Vaccine Elderly Persons Repeated Vaccination seroprotection Rate
下载PDF
Hepatitis B Virus (HBV) Infection in Patients at Pasteur Institute of Dakar in Senegal from 2016 to 2020: Prevalence and Seroprotection Level
3
作者 Diop Abdou Ndiaye Babacar +5 位作者 Diallo Thierno Abdoulaye Mahou Chantal Guèye Omar Dubrous Philippe Dubrous Philippe Seck Abdoulaye 《Open Journal of Medical Microbiology》 CAS 2023年第1期68-77,共10页
Hepatitis B virus (HBV) infection is highly endemic in Senegal. Vaccination of all children against HBV was introduced in 1999 and included in Expanded Programme on Immunisation in 2005. The aim of this study was to a... Hepatitis B virus (HBV) infection is highly endemic in Senegal. Vaccination of all children against HBV was introduced in 1999 and included in Expanded Programme on Immunisation in 2005. The aim of this study was to assess the prevalence and immune status against HBV in patients received at Pasteur Institut in Dakar, Senegal. Methods: Between January 2016 and December 2020, patients aged between 1 and 96 years received laboratory were included in the study. Serum samples were analysed for HBV serology (HBs antigen: HBsAg, HBs antibody: HBsAb and HBc antibody: HBcAb) using ARCHITECT<sup>?</sup> analyser. Patients with anti-HBs antibody levels (HBsAb ≥ 10 IU/l) were considered seroprotected against HBV. Results: A total of 5629 patients were analysed with a mean age of 39 years and extremes from 1 to 96 years. The most represented age group was 31 - 45 years with 38.4%. HBsAg was present in 520 patients (9.2%) and was signed by sex and age group. Anti-HBc antibodies were found in 52.7% of patients and 1603 (28.48%) had isolated anti-HBs antibodies reflecting proportion of people vaccinated at the time of the study. However, 2143 patients (41.9%) had no seroprotection (HBsAb 10 IU/L) and 640 (12.6%) had strong seroprotection defined as HBsAb > 1000 IU/L. Conclusion: Our results show a significant presence of virus in Senegalese population and low vaccination coverage, especially in adults. Evaluation of HBsAb levels and provision of HBV booster shots should be considered for children in Senegal. 展开更多
关键词 HBSAB HBsAg HBV SEROPREVALENCE seroprotection VACCINATION
下载PDF
Efficacy of Shanvac-B recombinant DNA hepatitis B vaccine in health care workers of Northern India 被引量:1
4
作者 Varsha Thakur Nirupma T Pati +1 位作者 Rajkumar C Gupta Shiv K Sarin 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS 2010年第4期393-397,共5页
BACKGROUND: Health care workers (HCWs) constitute a high-risk population of HBV infection. There are limited data on the efficacy of vaccination in HCWs in India. This study was to evaluate the efficacy of indigenous ... BACKGROUND: Health care workers (HCWs) constitute a high-risk population of HBV infection. There are limited data on the efficacy of vaccination in HCWs in India. This study was to evaluate the efficacy of indigenous recombinant hepatitis B vaccine, Shanvac-B, in HCWs. METHODS: In 597 HCWs screened before the vaccination, 216 (36.2%) showed the presence of at least one of the markers of HBV/HCV infection. Of the remaining 381 (63.8%) HCWs who were considered for vaccination, only 153 (age 18-45 years; 48 males and 105 females) were available for final assessment. These HCWs received 20 μg of vaccine at 0, 1 and 6 months. They were asked for the reactogenicity and monitored for the seroprotective efficacy of the vaccination. Anti-HBs titres were measured after vaccination at 1, 2 and 7 months. The presence of anti-HBs titers equal to 1 MIU/ml was considered as seroconversion and that of titres greater than 10 MIU/ml as seroprotection. RESULTS: After vaccination, 32 males (67%) and 76 females (72%) showed seroconvertion; finally 12 (25%) of the males and 47 (45%) of the females were seroprotected. Seroprotection at 2 and 7 months was more dominant in the females than in the males (96% vs. 56%, P=0.001, 100% vs. 85%, P=0.0001), respectively. Geometric mean titres of anti-HBs after vaccination were also higher in the females than in the males (257±19.7 vs. 29±1.88 MIU/ml, P=0.01, 1802±35.2 vs. 306±13.6 MIU/ml, P≤0.05, 6465±72 vs. 2142±73.6 MIU/ml, P<0.05). Seven male HCWs showed unsatisfactory response, non-response (n=3, 6%) and hypo-response (≤10 MIU/ml, n=4, 8%) at the end of vaccination. Smoking and alcoholism were significantly correlated with unsatisfactory response. No significant adverse effects of vaccination were observed in any HCW.CONCLUSIONS: The presence of HBsAg in HCWs indicates that a high proportion of HCWs are infected with HBV and HCV in India. Recombinant indigenous vaccine Shanvac-B is highly efficacious in HCWs, and its immunogenicity is significantly higher in females than in males. 展开更多
关键词 health care workers hepatitis B virus hepatitis C virus seroprotection IMMUNOGENICITY Shanvac-B
下载PDF
不同剂量重组酵母乙型肝炎疫苗成人免疫后效果比较 被引量:10
5
作者 袁跃彬 王仲倩 +1 位作者 马西平 张根宏 《解放军预防医学杂志》 CAS 北大核心 2003年第3期176-179,共4页
目的 :对比不同剂量重组酵母乙型肝炎疫苗的免疫效果 ,为探讨适合于我国成人的合适免疫剂量提供依据。方法 :2 0 0名符合要求的研究对象随机分为A、B、C、D共 4个剂量组 ,均按 0、1、6个月免疫程序接种 3次重组酵母乙型肝炎疫苗 ,4组剂... 目的 :对比不同剂量重组酵母乙型肝炎疫苗的免疫效果 ,为探讨适合于我国成人的合适免疫剂量提供依据。方法 :2 0 0名符合要求的研究对象随机分为A、B、C、D共 4个剂量组 ,均按 0、1、6个月免疫程序接种 3次重组酵母乙型肝炎疫苗 ,4组剂量分别为每次 5 μg、10 μg、15 μg和 2 0 μg。 结果 :全程免疫后 1个月时 ,4个组抗 -HBs阳转率分别为 75 .0 0 %、91.84 %、95 .6 5 %、97.87%,组间差别有显著性 (P <0 .0 1) ;抗 -HBs几何平均滴度 (GMT)分别是 197.4mIU·mL 1、315 .6mIU·mL 1、4 0 3.6mIU·mL 1和 4 77.8mIU·mL 1,组间差别亦有显著性 (P <0 .0 1)。年龄、体重指数、性别对免疫效果有影响。随着免疫剂量的增加 ,不良反应率随之增加 ,2 0 μg组注射部位疼痛发生率为 7.5 9%,5 μg组注射部位疼痛发生率为 2 .0 3%,差别有显著性 (P <0 .0 5 )。 结论 :我国健康成人按 0、1、6个月方案接种 3次不同剂量重组酵母乙型肝炎疫苗 ,结果表明 ,每次接种2 0 μg的免疫效果最好 ,但不良反应率也最高。故推荐 ,在健康成人以 10 μg而 35岁以上乙肝高危人群以 2 0 μg的免疫剂量较为适宜。 展开更多
关键词 重组酵母乙型肝炎疫苗 抗体阳转率 抗体几何平均滴度 免疫剂量
下载PDF
流感灭活疫苗免疫持久性的Meta分析
6
作者 胡昱 龚杰 《国际流行病学传染病学杂志》 CAS 2024年第4期251-257,共7页
目的评价流感灭活疫苗(inactivated influenza vaccine,IIV)免疫持久性。方法检索美国国家医学图书馆数据库、考克兰Cochrane协作网图书馆、美国临床试验数据库等外文电子数据库、中国生物医学文献数据库、中国期刊全文数据库、万方全... 目的评价流感灭活疫苗(inactivated influenza vaccine,IIV)免疫持久性。方法检索美国国家医学图书馆数据库、考克兰Cochrane协作网图书馆、美国临床试验数据库等外文电子数据库、中国生物医学文献数据库、中国期刊全文数据库、万方全文数据库,将评价≥6月龄健康人群接种IIV的免疫原性研究纳入本次分析,合并计算疫苗接种前和接种后不同时间点,不同疫苗毒株的抗体几何平均滴度(geometric mean titer,GMT)的均数差(mean difference,MD),以及血清抗体保护率(seroprotection rate,SPR)的率差(risk difference,RD)。使用Review Manager 5.4进行Meta分析。结果共纳入8篇文献,包括6篇随机对照试验和2篇队列研究。接种佐剂IIV3(IIV3-adj)或IIV3/IIV4疫苗后6个月,儿童和成人的血清抗体GMT和SPR水平显著提高,其中儿童接种IIV3-adj的GMT MD为2.50(95%CI:2.06~2.94),SPR RD为0.62(95%CI:0.50~0.74);成人接种IIV3-adj的GMT MD为0.71(95%CI:0.47~0.95),SPR RD为0.19(95%CI:0.11~0.28)。同时,儿童和成人接种IIV3-adj和IIV3后1个月和6个月的血清抗体GMT和SPR水平均呈现明显下降趋势,其中儿童1个月时GMT的MD为1.17(95%CI:0.78~1.56),6个月时降至0.98(95%CI:0.77~1.18),SPR在1个月时的RD为0.30(95%CI:0.06~0.53),6个月时降至0.29(95%CI:0.14~0.44);成人1个月时GMT的MD为0.27(95%CI:0.20~0.33),6个月时降至0.21(95%CI:0.12~0.29),SPR在1个月时的RD为0.06(95%CI:0.01~0.11),6个月时降至0.06(95%CI:-0.02~0.15)。结论IIV免疫持久性至少可以维持一个完整的流感流行季,建议在流感流行季到来之前完成IIV接种。 展开更多
关键词 流感灭活病毒疫苗 免疫效果 持久性 META分析 血清抗体保护率
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部